Alan Dunton Biography and Net Worth

Director of CorMedix

Alan W. Dunton, M.D. joined the CorMedix board in February 2019. He has devoted his 35-year career to the discovery and development of new drug products. Most recently, he was Senior Vice President of Research and Development at Purdue Pharmaceuticals L.P., based in Stamford, CT. During his career, Dr. Dunton has built a successful consulting company, Danerius LLC. He was also chief executive officer of two biotech companies, and was President and Managing Director of the Janssen Research Foundation, the R&D and regulatory arm of the pharmaceutical division of Johnson & Johnson. His earlier experience includes positions at Roche, Syntex, and Novartis. Dr. Dunton holds an M.D. from New York University School of Medicine, where he completed a residency in internal medicine. He was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center. In 1987, he was awarded The Nellie Westerman Prize from the American Federation for Clinical Research for his work in medical ethics. Dr. Dunton currently serves on the boards of two public companies, Palatin Technologies, Inc. and Oragenics, Inc. He is also a member of the board of Cytogel Pharma LLC, a private bio-pharmaceutical development company focused on acquiring promising early-stage programs.

What is Alan W. Dunton's net worth?: The estimated net worth of Alan W. Dunton is at least $258.41 thousand as of December 30th, 2025. Dunton owns 40,250 shares of CorMedix stock worth more than $258,405 as of March 23rd. This net worth evaluation does not reflect any other investments that Dunton may own. Learn More about Alan W. Dunton's net worth.
How do I contact Alan W. Dunton?: The corporate mailing address for Dunton and other CorMedix executives is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. CorMedix can also be reached via phone at (908) 517-9500 and via email at [email protected]. Learn More on Alan W. Dunton's contact information.
Has Alan W. Dunton been buying or selling shares of CorMedix?: Alan W. Dunton has not been actively trading shares of CorMedix within the last three months. Most recently, Alan W. Dunton sold 20,000 shares of the business's stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $13.00, for a transaction totalling $260,000.00. Following the completion of the sale, the director now directly owns 40,250 shares of the company's stock, valued at $523,250. Learn More on Alan W. Dunton's trading history.
Who are CorMedix's active insiders?: CorMedix's insider roster includes Alan Dunton (Director), Elizabeth Hurlburt (EVP), Myron Kaplan (Director), Steven Lefkowitz (Director), Erin Mistry (EVP), and Joseph Todisco (CEO). Learn More on CorMedix's active insiders.
Are insiders buying or selling shares of CorMedix?: During the last twelve months, CorMedix insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $275,500.00. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 253,997 shares worth more than $3,258,817.44. The most recent insider tranaction occured on December, 30th when Director Alan W Dunton sold 20,000 shares worth more than $260,000.00. Insiders at CorMedix own 3.1% of the company. Learn More about insider trades at CorMedix.
Information on this page was last updated on 12/30/2025.

Alan W. Dunton Insider Trading History at CorMedix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/30/2025	Sell	20,000	$13.00	$260,000.00	40,250
9/12/2025	Sell	10,000	$13.13	$131,300.00	40,250
8/12/2020	Buy	5,000	$3.95	$19,750.00	6,250

Alan W. Dunton Buying and Selling Activity at CorMedix

CorMedix Company Overview

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Today's Range

Now: $6.42

$6.28

$6.51

50 Day Range

MA: $7.14

$6.25

$8.17

2 Week Range

Now: $6.42

$5.60

$17.43

Volume

1,428,271 shs

Average Volume

2,607,843 shs

Market Capitalization

$507.50 million

P/E Ratio

3.21

Dividend Yield

N/A

Beta

1.31